SpringerProtocols: Abstract: 12. The HUVEC/Matrigel Assay: An In Vivo Assay of Human Angiogenesis Suitable for Drug Validation

12. The HUVEC/Matrigel Assay: An In Vivo Assay of Human Angiogenesis Suitable for Drug Validation

By: Dag K. Skovseth², Axel M. Küchler², Guttorm Haraldsen²

Abstract

Full Text

Download PDF (1709K)

The future ability to manipulate the growth of new blood vessels (angiogenesis) holds great promise for treating ischemic disease and cancer. Several models of human in vivo angiogenesis have been described, but they seem to depend on transgenic support and have not been validated in a therapeutic context. Here, we describe an in vivo assay that mimics human angiogenesis in which native human umbilical vein-derived endothelial cells are suspended in a liquid laminin/collagen gel (Matrigel), injected into immunodeficient mice, and develop into mature, functional vessels that vascularize the Matrigel plug in the course of 30 d. Moreover, we demonstrate how to target this process therapeutically by sustained delivery of the angiogenesis inhibitor endostatin from subcutaneously implanted microosmotic pumps.

Affiliation(s): (2) Institute of Pathology, Rikshospitalet University Hospital, Oslo, Norway

Book Title: Target Discovery and Validation Reviews and Protocols: Volume 1, Emerging Strategies for Targets and Biomarker Discovery

Series: Methods in Molecular Biology | Volume: 360 | Pub. Date: Oct-15-2006 | Page Range: 253-268 | DOI: 10.1385/1-59745-165-7:253

Subject: Pharmacology/Toxicology

Key Words: Adoptive transfer - angiogenesis - endostatin - human umbilical vein-derived endothelial cells - HUVECs - Matrigel - RAG2 mice

References

Download References

1.	Risau, W. (1997) Mechanisms of angiogenesis. Nature 386, 671–674.

2.	Carmeliet, P. (2000) Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389–395.

3.	Folkman, J. (2003) Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643–651.

4.	Losordo, D. W. and Dimmeler, S. (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part II: Cell-based therapies. Circulation 109, 2692–2697.

5.	Boehm, T., Folkman, J., Browder, T., and O’Reilly, M. S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407.

6.	Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342.

7.	Ferrara, N., Hillan, K. J., and Novotny, W. (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys. Res. Commun. 333, 328–335.

8.	Auerbach, R., Lewis, R., Shinners, B., Kubai, L., and Akhtar, N. (2003) Angiogenesis assays: a critical overview. Clin. Chem. 49, 32–40.

9.	Folkman, J. (997) Proceedings: tumor angiogenesis factor. Cancer Res. 34, 2109–2113.

10.	Gimbrone, M. A., Jr., Leapman, S. B., Cotran, R. S., and Folkman, J. (1973) Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J. Natl. Cancer Inst. 50, 219–228.

11.	Passaniti, A., Taylor, R. M., Pili, R., et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 4, 519–528.

12.	Nor, J. E., Christensen, J., Mooney, D. J., and Polverini, P. J. (1999) Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154, 375–384.

13.	Nor, J. E., Peters, M. C., Christensen, J. B., et al. (2000) Engineering and characterization of functional human microvessels in immunodeficient mice. Lab. Investig. 81, 453–463.

14.	Schechner, J. S., Nath, A. K., Zheng, L., et al (2000) In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc. Natl. Acad. Sci. USA 97, 9191–9196.

15.	Enis, D. R., Shepherd, B. R., Wang, Y., et al. (2005) Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. Proc. Natl. Acad. Sci. USA 102, 425–430.

16.	Skovseth, D. K., Yamanaka, T., Brandtzaeg, P., Butcher, E. C., and Haraldsen, G. (2002) Vascular morphogenesis and differentiation after adoptive transfer of human endothelial cells to immunodeficient mice. Am. J. Pathol. 160, 1629–1637.

17.	Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–31.

18.	Carmeliet, P. and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249–257.

19.	Skovseth, D. K., Veuger, M. J., Sorensen, D. R., De Angelis, P.M., and Haraldsen, G. (2005) Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 105, 1044–1051.

20.	Cao, Y. (2001) Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33, 357–369.

21.	Marneros, A. G. and Olsen, B. R. (2001) The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 20, 337–345.

22.	O’Reilly, M. S., Boehm, T., Shing, Y., et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88, 277–285.

23.	Dhanabal, M., Ramchandran, R., Volk, R., et al. (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59, 189–197.

24.	Read, T. A., Sorensen, D. R., Mahesparan, R., et al. (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. 19, 29–34.

25.	Sorensen, D. R., Read, T. A., Porwol, T., et al. (2002) Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neurooncology 4, 1–8.

26.	Sorensen, D. R., Leirdal, M., Iversen, P. O., and Sioud, M. (2002) Combination of endostatin and a protein kinase C alpha DNA enzyme improves the survival of rats with malignant glioma. Neoplasia 4, 474–479.

27.	Eder, J. P., Jr., Supko, J. G., Clark, et al. (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 23, 772–784.

28.	Herbst, R. S., Hess, K. R., Tran, H. T., et al. (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792–3803.

29.	Thomas, J. P., Arzoomanian, R. Z., Alberti, D., et al. (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21, 223–231.

30.	Abdollahi, A., Hlatky, L., and Huber, P. E. (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist. Updat. 8, 59–74.

31.	Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242–245.

32.	Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745–2756.

Comments (Loading...)

Post comment/View all comments